This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Elan Reports Fourth Quarter And Full-Year 2012 Financial Results

Stocks in this article: ELN

Quarter 4, 2012 Operating Performance (excluding Tysabri)

Adjusted EBITDA losses from continuing operations were $41.5 million for the fourth quarter of 2012, compared to $47.4 million for the fourth quarter of 2011. Operating loss excluding other net charges for the fourth quarter of 2012 decreased to $48.1 million, compared to $56.0 million for the fourth quarter of 2011. These improvements principally reflect the impact of the operations restructuring in the fourth quarter of 2012.

The net income from continuing operations for the fourth quarter of 2012 of $91.3 million includes other charges of $59.3 million (see page 13), a net charge on debt retirement of $76.1 million (see page 14) and a $304.2 million tax credit primarily related to the recognition of a deferred tax asset expected to be utilized in relation to the expected gain on sale of Tysabri in 2013 (see page 16). The net loss from continuing operations for the fourth quarter of 2011 of $189.9 million includes other charges of $21.4 million and a net charge on debt retirement of $47.0 million.

The net income of $152.8 million (2011: $134.7 million net loss) includes net income from discontinued operations of $61.5 million (2011: $55.2 million), related to the Tysabri, Prothena and EDT businesses. For further information please refer to page 17 and Appendix III on page 24.

Full-Year 2012 Operating Performance (excluding Tysabri)

Adjusted EBITDA losses from continuing operations decreased to $168.1 million for the full year 2012, from $174.9 million for the full-year 2011. Operating loss excluding other net charges for the full-year 2012 decreased to $208.6 million, from $210.8 million for the full-year 2011. These improvements reflect lower operating expenses, following the operations restructuring in the fourth quarter of 2012.

The net loss from continuing operations for the full-year 2012 of $372.7 million includes other net charges of $168.9 million (see page 13), a net charge on debt retirement of $76.1 million (see page 14), an impairment charge of $117.3 million related to the Janssen AI equity method investment (see page 15) and a $304.2 million tax credit related primarily to the recognition of a deferred tax asset expected to be utilized in relation to the expected gain on sale of Tysabri in 2013 (see page 16). The net loss from continuing operations for the full-year 2011 of $453.5 million includes other net charges of $24.3 million and a net charge on debt retirement of $47.0 million.

The net loss of $137.4 million (2011: $560.5 million net income) includes net income from discontinued operations of $235.3 million (2011: $1,014.0 million), related to the Tysabri, Prothena and EDT businesses. For further information please refer to page 17 and Appendix IV on page 25.

Pro Forma Revenue (including Tysabri)

For the fourth quarter of 2012, revenue increased by 18% to $319.8 million from $271.0 million for the fourth quarter of 2011. For the full-year 2012, revenue increased by 13% to $1,202.8 million from $1,068.1 million for the full-year 2011.

Three Months Ended December 31

   

Twelve Months Ended December 31

2011 US$m

 

2012 US$m

     

2011 US$m

 

2012 US$m

  Product revenue  
(0.4) Maxipime 0.4
0.4 Azactam 0.9 (0.5)
0.4 0.2 Royalties 2.7 0.7
0.4 0.2 Total revenue from continuing operations 4.0 0.2
196.4 243.0 Tysabri – U.S. 746.5 886.0
74.2 76.6 Tysabri – ROW 317.6 316.6
270.6 319.6 Total Tysabri 1,064.1 1,202.6
271.0 319.8 Total pro forma revenue 1,068.1 1,202.8
 

Elan ceased distributing Azactam and Maxipime in 2010. The revenue and adjustments for these products in 2011 and 2012 relates to adjustments to discounts and allowances associated with sales prior to the cessation of distribution.

4 of 16

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs